Cost‐effectiveness of 123I‐FP‐CIT SPECT in the differential diagnosis of essential tremor and Parkinson's disease in Italy

Economic evaluation (Italian NHS perspective) modeling 123I‐FP‐CIT SPECT (DaTSCAN®) compared to clinical judgment alone for differentiating essential tremor (ET) from Parkinson's Disease (PD). A 5‐year Markov model was constructed to assess the cost‐effectiveness of 123I‐FP‐CIT SPECT to differentiate ET from PD in patients referred to a movement disorder specialist in Italy. Published data and a double‐round, Delphi panel of 12 specialists populated the model. Effectiveness was expressed as the projected Years on potentially beneficial therapy (PBTYs). Costs were expressed in Euros (2005 values). The model suggests that over 5 years, the “current” diagnostic pathway generated an average of 2.3 PBTYs/patient at an estimated cost of €8,864. 123I‐FP‐CIT SPECT generated an average of 4.1 PBTYs/patient at an estimated cost of €8,422, which represented an additional 1.8 PBTYs at a cost saving of €442/patient (€341 when discounted at 5%). The estimated cost‐effectiveness of 123I‐FP‐CIT SPECT is under €1,000 per PBTY gained when the underlying disease prevalence is high (55–70%), and cost‐saving at prevalence under 55%. 123I‐FP‐CIT SPECT is likely to be regarded as economically advantageous to differentiate ET from PD, increasing time on potentially beneficial therapy at a lower overall cost to the healthcare system. © 2008 Movement Disorder Society

[1]  J. Jankovic,et al.  The evolution of diagnosis in early Parkinson disease. Parkinson Study Group. , 2000, Archives of neurology.

[2]  P. Calabresi,et al.  Prevalence of essential tremor in the territory of Lake Trasimeno, Italy: Results of a population‐based study , 2007, Movement disorders : official journal of the Movement Disorder Society.

[3]  J D Speelman,et al.  One-day protocol for imaging of the nigrostriatal dopaminergic pathway in Parkinson's disease by [123I]FPCIT SPECT. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[4]  J. Seibyl,et al.  Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[5]  M. Weinstein,et al.  Identifying and Valuing Outcomes , 1996 .

[6]  M. Gold Cost-effectiveness in health and medicine , 2016 .

[7]  J. Booij,et al.  Practical benefit of [123I]FP-CIT SPET in the demonstration of the dopaminergic deficit in Parkinson's disease , 2005, European Journal of Nuclear Medicine.

[8]  P B Hoffer,et al.  SPECT imaging of dopamine transporters in human brain with iodine-123-fluoroalkyl analogs of beta-CIT. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[9]  Thomas Behr,et al.  Dopamine transporter imaging and SPECT in diagnostic work‐up of Parkinson's disease: A decision‐analytic approach , 2003, Movement disorders : official journal of the Movement Disorder Society.

[10]  Robert B. Innis,et al.  Iodine-123-β-CIT and Iodine-123-FPCIT SPECT Measurement of Dopamine Transporters in Healthy Subjects and Parkinson's Patients , 1998 .

[11]  E. Tolosa,et al.  Impact of dopamine transporter SPECT using 123I‐Ioflupane on diagnosis and management of patients with clinically uncertain parkinsonian syndromes , 2004, Movement disorders : official journal of the Movement Disorder Society.

[12]  Marco Cosentino,et al.  Medical healthcare use in Parkinson's disease: survey in a cohort of ambulatory patients in Italy , 2005, BMC health services research.

[13]  W. Rocca,et al.  Prevalence of Parkinson's disease and other types of parkinsonism , 1992, Neurology.

[14]  J B Habraken,et al.  Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[15]  Andrew J. Lees,et al.  Improved accuracy of clinical diagnosis of Lewy body Parkinson’s disease , 2001, Neurology.

[16]  Jan Booij,et al.  Iodine-123-N-ω-Fluoropropyl-2β-Carbomethoxy-3β-(4-Iodophenyl)Tropane SPECT in Healthy Controls and Early-Stage, Drug-Naive Parkinson's Disease , 1998 .

[17]  P. Hobson,et al.  Accuracy of diagnosis in patients with presumed Parkinson's disease. , 1999, Age and ageing.

[18]  E. Tolosa,et al.  Role of DAT‐SPECT in the diagnostic work up of Parkinsonism , 2007 .

[19]  S. Gacinovic,et al.  Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]‐FP‐CIT SPECT imaging: The [123I]‐FP‐CIT study group , 2000, Movement disorders : official journal of the Movement Disorder Society.

[20]  J. C. Stoof,et al.  Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iod ophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[21]  D. Inzitari,et al.  Parkinson's disease and parkinsonism in a longitudinal study: two-fold higher incidence in men. ILSA Working Group. Italian Longitudinal Study on Aging. , 2000, Neurology.